H2 Global Group, together with its subsidiary H2 Medical Technologies, has entered a decisive growth stage following strong recognition at LSI Europe 2025 in London. The group presented its breakthrough approach to preventing and treating neurodegenerative diseases, including Alzheimer’s, confirming its position among global leaders in the MedTech and HealthTech sectors.

At the core of this innovation is a prototype medical device for controlled hydrogen therapy, developed by H2 Medical Technologies. The device is designed for patients with mild cognitive impairment, a condition that often precedes Alzheimer’s. Non-invasive and suitable for both clinical and home use, it is based on a patented method pioneered by a Japanese team led by Professor Shigeo Ohta, co-owner of H2 Global Group. Research indicates that molecular hydrogen can protect brain cells, slow inflammation, and support neuronal metabolism and connectivity.

“Hydrogen is the smallest molecule in the universe, yet it can protect our most valuable assets – memory and independence,” explains Prof. Ohta.

Group founder David Maršálek, who has been developing hydrogen technologies since 2011, adds: “Our mission is to launch the world’s first hydrogen-based medical device for Alzheimer’s prevention and therapy support. With strong scientific evidence, patent protection, and an experienced team, we are positioned to succeed.”

Between 2021 and 2025, H2 Global Group raised over $18M in Seed funding, built a network of 20,000 end-customers and 50+ B2B partners, and exceeded revenues of circa $7.4M. Current transactions value the group at circa $77M.

Now entering Series A, the group plans to raise $25–30 million to fund global expansion into Europe, the U.S., the Middle East, and Africa, complete clinical trials, and secure EU and FDA registrations. Revenue projections forecast growth to nearly $48M by 2029.

The portfolio extends beyond the medical device. H2 Medical Technologies supplies hydrogen generators and therapeutic systems to spas, sports clubs, physiotherapy practices or dental clinics. Its solutions are also approved for veterinary use. In parallel, H2 Pharm develops consumer products such as H2 Premium Water®, H2 Brain®, H2 Forte®, and H2 Dent Care®, which are commercially successful and distributed via e-commerce and a B2B network.

“Such opportunities are rare,” concludes Maršálek. “When future textbooks are written, our investors will say: I was there. Hydrogen is not only energy source but a molecule of lifeconnecting the world. Invest in Hydrogen!”

Source: ap.news.com

H2 Medical Technologies, part of the H2 Global Group, has developed the world’s first functional hydrogen-based therapy medical device prototype for clinical trials — aimed at both preventing and treating Alzheimer’s disease.

Today, more than 6.5 million Americans and 50 million people worldwide are living with Alzheimer’s and other forms of dementia. According to the World Health Organization, this number could triple by 2050, placing an immense burden on families and healthcare systems. Despite decades of research, no effective solution has been found — until now.

“This is not another experiment — it is the first technology in the world with the potential to prevent Alzheimer’s disease before it even starts, while supporting those already affected,” says David Marsalek, founder and CEO of H2 Global Group. The company believes its effectiveness will be further confirmed in an upcoming new clinical trial. “Our mission is clear: to turn decades of research into real hope for millions of families around the world. We are part of a strong vision of a society where hydrogen is the molecule of life that connects the world.”

From the Lab to the Global Stage

H2 Global Group will present this breakthrough at LSI Europe 2025 in London, one of the world’s most prestigious MedTech and HealthTech conferences. The project builds on 30+ years of research and patents developed with Professor Shigeo Ohta, a global leader in molecular hydrogen science and co-founder of H2 Global Group.

More Than Medicine: A New Era of Brain Health

While the immediate focus is Alzheimer’s, potential applications extend to neurological disorders, brain regeneration, and healthy aging.

Alongside its medical device, H2 Global Group has launched consumer products such as H2 Premium Water® and H2 Brain®, a world-first two-phase dietary supplement that stimulates molecular hydrogen production through the gut microbiome. The company is also the only certified global manufacturer authorized to use hydrogen-based medical devices in veterinary medicine.

Today, its hydrogen-based solutions are already being adopted by wellness centers, rehabilitation clinics, dental practices, and elite sports organizations across Europe — underscoring the broad potential of the technology.

Source: finance.yahoo.com